<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264576</url>
  </required_header>
  <id_info>
    <org_study_id>V58P5</org_study_id>
    <nct_id>NCT00264576</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults</brief_title>
  <official_title>A Phase 2, Observer-Blinded, Randomized, Multicenter Study in Healthy Adults to Evaluate Safety and Tolerability and to Compare Immunogenicity of a Single Dose of Either an Investigational Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture or a US-licensed Trivalent Inactivated Influenza Vaccine (Fluvirin®) Produced in Embryonated Hen Eggs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines and Diagnostics (formerly Chiron Vaccines)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of cell
      culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin
      vaccine administered to healthy adults ages 18 &lt; 50 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT) After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method.</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>Non-inferiority was measured by the ratio of postvaccination geometric mean titers (cTIV vs. eTIV_f) against all three vaccine strains as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT) After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANCOVA Method.</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>Non-inferiority was measured by the ratio of postvaccination geometric mean titers (cTIV vs. eTIV_f) against all three vaccine strains as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method.</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>Geometric mean ratio (GMR) of Day 22 / Day 1 geometric mean antibody titers was assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (Day22/Day1) in HI antibody titer is &gt; 2.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANCOVA Method.</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>Geometric mean ratio (GMR) of Day 22 / Day 1 geometric mean antibody titers was assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (Day22/Day1) in HI antibody titer is &gt; 2.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) Before and After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>Antibody titers as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Haemagglutination Inhibition (HI) Antibody Titer ≥ 40.</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>Antibody titers as assessed by egg-derived antigen and cell-derived antigen HI assay.
This criterion is met according to European (CHMP) guideline if the percentages of subjects achieving HI titers ≥40 is &gt;70%. According to the US Center for Biologics Evaluation and Research (CBER) guideline, the criterion is also met if the lower limit of the 95% CI for percentages of subjects achieving seroprotection (HI antibody titer ≥1:40) is ≥70%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Seroconversion.</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>As the definition for seroconversion/significant increase from CHMP guideline CPMP/BWP/214/96 corresponds to that of seroconversion from the May 2007 CBER guidance, the analysis of this immunogenicity endpoint is presented as seroconversion. Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40, or prevaccination HI titer ≥10 and a ≥4-fold increase in postvaccination HI antibody titer, on day 22. CBER criterion is met if the lower limit of the 95% CI for percentages of subjects achieving seroconversion for HI antibody (at least a 4-fold rise in HI antibody titer) postvaccination is ≥40%. CHMP criterion is also met if the percentages of subjects achieving seroconversion is &gt;40%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Local and Systemic Reactions</measure>
    <time_frame>7 days postvaccination</time_frame>
    <description>Safety and tolerability of cTIV and eTIV_f postvaccination.
Difference between demography and safety numbers was due to one misrandomization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">613</enrollment>
  <condition>Influenza Disease; Flu</condition>
  <arm_group>
    <arm_group_label>cTIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received one dose of egg-derived trivalent vaccine (TIV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine</intervention_name>
    <arm_group_label>cTIV</arm_group_label>
    <arm_group_label>TIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        18 to &lt;50 years of age;

          1. able to comprehend and follow all required study procedures;

          2. able and willing to provide written informed consent prior to study entry;

          3. available for all the visits scheduled in the study;

          4. in general good health as determined by:

               1. subject-reported medical history,

               2. physical examination by a qualified study nurse, a physician's assistant, or a
                  physician,

               3. clinical judgment of the investigator; among all female volunteers, evidence of a
                  negative pregnancy test conducted on the same day as and prior to study
                  vaccination, and agreement to practice adequate contraception for at least 6
                  weeks after vaccination as further described in the protocol.

        Exclusion Criteria:

          1. received influenza vaccine within the past 6 months;

          2. laboratory-confirmed influenza disease in the past 6 months;

          3. any acute respiratory disease or infection requiring systemic antibiotic or antiviral
             therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable) or
             fever ≥38°C (100.4°F) within the past 3 days;

          4. receipt of another investigational agent within 90 days or before completion of the
             safety follow-up period in another study, whichever was longer, prior to enrollment,
             and unwilling to refuse participation in another investigational study through the end
             of the study;

          5. any history of or current serious disease, such as: d) cancer (except for benign or
             localized skin cancer), e) autoimmune disease (including rheumatoid arthritis), f)
             advanced arteriosclerotic disease or diabetes mellitus, g) chronic obstructive
             pulmonary disease (COPD), h) acute, chronic, or progressive hepatic disease, i) acute,
             chronic, or progressive renal disease, j) congestive heart failure, k) bleeding
             diathesis, l) an inherited genetic anomaly (known cytogenic disorders, e.g., Down's
             Syndrome), m) any other serious, acute, or chronic disease including progressive
             neurological disease or seizure disorder unrelated to fever;

          6. surgery or hospitalization planned during the study period;

          7. history of any anaphylaxis, serious vaccine reactions, vaccine-associated
             oculorespiratory syndrome, or allergy to eggs, egg products, mercury-containing
             compounds (such as sodium-ethyl-mercuro-thio-salicylate), or any other vaccine
             component or component of the potential packaging materials (latex);

          8. known or suspected disease of the immune system, or receiving immunosuppressive
             therapy, including use of: n) systemic corticosteroids, known to be associated with
             suppression of the hypothalamic-pituitary-adrenal (HPA) axis (i.e., systemic
             corticosteroids [15 mg/day of prednisone or its equivalent] or chronic use of inhaled
             high potency corticosteroids [budesonide 800 μg/day or fluticasone 750 μg/day]), both
             within the previous 60 days, o) receipt of immunostimulants within 60 days, p) receipt
             of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives
             within the 3 months prior to study entry or anticipated during the full length of the
             study;

          9. at high risk for developing an immunocompromising disease;

         10. history of (or current) drug or alcohol abuse that in the investigator's opinion would
             interfere with safety of the subject or the evaluation of study objectives;

         11. pregnant or breastfeeding;

         12. if female of childbearing potential, refusal to use a reliable contraceptive method,
             as described further in the protocol, during the first 6 weeks after vaccination;

         13. if female of childbearing potential and sexually active, has not used any of the
             following birth control methods for the specified time period prior to study entry:

               1. hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring),
                  barrier (e.g., condom with spermicide or diaphragm with spermicide), or
                  intrauterine device (e.g., IUD) for 2 months or more prior to study entry,

               2. monogamous relationship with vasectomized partner: partner has been vasectomized
                  for 6 months or more prior to the subject's study entry;

         14. obese (e.g., with a body mass index [BMI] ≥35, where BMI reflects obesity and not high
             muscle mass);

         15. any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives or might interfere with the safety of the study
             subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis. 2009 Sep 15;200(6):849-57. doi: 10.1086/605506.</citation>
    <PMID>19673652</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2005</study_first_posted>
  <results_first_submitted>December 20, 2012</results_first_submitted>
  <results_first_submitted_qc>December 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2013</results_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>flu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>cTIV</title>
          <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
        </group>
        <group group_id="P2">
          <title>eTIV_f</title>
          <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="304"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>cTIV</title>
          <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
        </group>
        <group group_id="B2">
          <title>eTIV_f</title>
          <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="308"/>
            <count group_id="B2" value="305"/>
            <count group_id="B3" value="613"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="8.8"/>
                    <measurement group_id="B2" value="34.2" spread="9.3"/>
                    <measurement group_id="B3" value="34" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="401"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT) After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method.</title>
        <description>Non-inferiority was measured by the ratio of postvaccination geometric mean titers (cTIV vs. eTIV_f) against all three vaccine strains as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_f</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method.</title>
          <description>Non-inferiority was measured by the ratio of postvaccination geometric mean titers (cTIV vs. eTIV_f) against all three vaccine strains as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="225" upper_limit="298"/>
                    <measurement group_id="O2" value="306" lower_limit="265" upper_limit="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" lower_limit="157" upper_limit="210"/>
                    <measurement group_id="O2" value="320" lower_limit="276" upper_limit="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" lower_limit="157" upper_limit="203"/>
                    <measurement group_id="O2" value="157" lower_limit="138" upper_limit="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="468" lower_limit="407" upper_limit="538"/>
                    <measurement group_id="O2" value="508" lower_limit="441" upper_limit="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" lower_limit="250" upper_limit="331"/>
                    <measurement group_id="O2" value="468" lower_limit="406" upper_limit="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" lower_limit="155" upper_limit="199"/>
                    <measurement group_id="O2" value="134" lower_limit="118" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for A/H1N1 strain as measured by HI egg-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination GMTs had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for A/H3N2 strain as measured by HI egg-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination GMTs had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for B strain as measured by HI egg-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination GMTs had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for A/H1N1 strain as measured by HI cell-culture-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination geometric mean titers (GMTs) had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for A/H3N2 strain as measured by HI cell-culture-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination geometric mean titers (GMTs) had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for B strain as measured by cell-culture-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination geometric mean titers (GMTs) had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method.</title>
        <description>Geometric mean ratio (GMR) of Day 22 / Day 1 geometric mean antibody titers was assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (Day22/Day1) in HI antibody titer is &gt; 2.5.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_f</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method.</title>
          <description>Geometric mean ratio (GMR) of Day 22 / Day 1 geometric mean antibody titers was assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (Day22/Day1) in HI antibody titer is &gt; 2.5.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.06" lower_limit="6.64" upper_limit="9.8"/>
                    <measurement group_id="O2" value="9.65" lower_limit="7.93" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O2" value="25" lower_limit="21" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.49" upper_limit="13"/>
                    <measurement group_id="O2" value="9.15" lower_limit="7.83" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.21" lower_limit="7.48" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="8.19" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O2" value="22" lower_limit="18" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8.92" upper_limit="12"/>
                    <measurement group_id="O2" value="7.6" lower_limit="6.54" upper_limit="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANCOVA Method.</title>
        <description>Geometric mean ratio (GMR) of Day 22 / Day 1 geometric mean antibody titers was assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (Day22/Day1) in HI antibody titer is &gt; 2.5.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_f</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANCOVA Method.</title>
          <description>Geometric mean ratio (GMR) of Day 22 / Day 1 geometric mean antibody titers was assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (Day22/Day1) in HI antibody titer is &gt; 2.5.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.76" lower_limit="6.36" upper_limit="9.47"/>
                    <measurement group_id="O2" value="9.32" lower_limit="7.64" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O2" value="25" lower_limit="22" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.14" upper_limit="13"/>
                    <measurement group_id="O2" value="8.86" lower_limit="7.57" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.76" lower_limit="7.08" upper_limit="11"/>
                    <measurement group_id="O2" value="9.64" lower_limit="7.8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O2" value="22" lower_limit="19" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8.76" upper_limit="12"/>
                    <measurement group_id="O2" value="7.46" lower_limit="6.41" upper_limit="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMT) Before and After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method</title>
        <description>Antibody titers as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_f</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) Before and After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANOVA Method</title>
          <description>Antibody titers as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Day 1) (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="27" upper_limit="39"/>
                    <measurement group_id="O2" value="32" lower_limit="26" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 22) (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="225" upper_limit="298"/>
                    <measurement group_id="O2" value="306" lower_limit="265" upper_limit="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 1) (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="42" upper_limit="62"/>
                    <measurement group_id="O2" value="50" lower_limit="41" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 22) (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="468" lower_limit="407" upper_limit="538"/>
                    <measurement group_id="O2" value="508" lower_limit="441" upper_limit="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 1) (egg derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="9.22" upper_limit="12"/>
                    <measurement group_id="O2" value="13" lower_limit="12" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22) (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" lower_limit="157" upper_limit="210"/>
                    <measurement group_id="O2" value="320" lower_limit="276" upper_limit="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 1) (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="14" upper_limit="18"/>
                    <measurement group_id="O2" value="21" lower_limit="19" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22) (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" lower_limit="250" upper_limit="331"/>
                    <measurement group_id="O2" value="468" lower_limit="406" upper_limit="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 1) (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="14" upper_limit="18"/>
                    <measurement group_id="O2" value="17" lower_limit="15" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 22) (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" lower_limit="157" upper_limit="203"/>
                    <measurement group_id="O2" value="157" lower_limit="138" upper_limit="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 1) (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="15" upper_limit="19"/>
                    <measurement group_id="O2" value="18" lower_limit="15" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 22) (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" lower_limit="155" upper_limit="199"/>
                    <measurement group_id="O2" value="134" lower_limit="118" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Haemagglutination Inhibition (HI) Antibody Titer ≥ 40.</title>
        <description>Antibody titers as assessed by egg-derived antigen and cell-derived antigen HI assay.
This criterion is met according to European (CHMP) guideline if the percentages of subjects achieving HI titers ≥40 is &gt;70%. According to the US Center for Biologics Evaluation and Research (CBER) guideline, the criterion is also met if the lower limit of the 95% CI for percentages of subjects achieving seroprotection (HI antibody titer ≥1:40) is ≥70%.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of cell- culture-derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_f</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Haemagglutination Inhibition (HI) Antibody Titer ≥ 40.</title>
          <description>Antibody titers as assessed by egg-derived antigen and cell-derived antigen HI assay.
This criterion is met according to European (CHMP) guideline if the percentages of subjects achieving HI titers ≥40 is &gt;70%. According to the US Center for Biologics Evaluation and Research (CBER) guideline, the criterion is also met if the lower limit of the 95% CI for percentages of subjects achieving seroprotection (HI antibody titer ≥1:40) is ≥70%.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Percentages</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="87" upper_limit="94"/>
                    <measurement group_id="O2" value="96" lower_limit="93" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="91" upper_limit="96"/>
                    <measurement group_id="O2" value="93" lower_limit="89" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B(cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="91" lower_limit="88" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Seroconversion.</title>
        <description>As the definition for seroconversion/significant increase from CHMP guideline CPMP/BWP/214/96 corresponds to that of seroconversion from the May 2007 CBER guidance, the analysis of this immunogenicity endpoint is presented as seroconversion. Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40, or prevaccination HI titer ≥10 and a ≥4-fold increase in postvaccination HI antibody titer, on day 22. CBER criterion is met if the lower limit of the 95% CI for percentages of subjects achieving seroconversion for HI antibody (at least a 4-fold rise in HI antibody titer) postvaccination is ≥40%. CHMP criterion is also met if the percentages of subjects achieving seroconversion is &gt;40%.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_f</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Seroconversion.</title>
          <description>As the definition for seroconversion/significant increase from CHMP guideline CPMP/BWP/214/96 corresponds to that of seroconversion from the May 2007 CBER guidance, the analysis of this immunogenicity endpoint is presented as seroconversion. Seroconversion is defined as prevaccination HI titer &lt;10 and postvaccination HI titer ≥40, or prevaccination HI titer ≥10 and a ≥4-fold increase in postvaccination HI antibody titer, on day 22. CBER criterion is met if the lower limit of the 95% CI for percentages of subjects achieving seroconversion for HI antibody (at least a 4-fold rise in HI antibody titer) postvaccination is ≥40%. CHMP criterion is also met if the percentages of subjects achieving seroconversion is &gt;40%.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Percentages</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="57" upper_limit="68"/>
                    <measurement group_id="O2" value="65" lower_limit="59" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="81" upper_limit="89"/>
                    <measurement group_id="O2" value="92" lower_limit="88" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="72" upper_limit="81"/>
                    <measurement group_id="O2" value="76" lower_limit="70" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="56" upper_limit="67"/>
                    <measurement group_id="O2" value="64" lower_limit="58" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="85" upper_limit="92"/>
                    <measurement group_id="O2" value="90" lower_limit="87" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B(cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="73" upper_limit="83"/>
                    <measurement group_id="O2" value="72" lower_limit="66" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT) After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANCOVA Method.</title>
        <description>Non-inferiority was measured by the ratio of postvaccination geometric mean titers (cTIV vs. eTIV_f) against all three vaccine strains as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_f</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) After 1 Dose of Cell-culture-derived Vaccine (cTIV) or Egg-derived Vaccine (eTIV_f), Using the ANCOVA Method.</title>
          <description>Non-inferiority was measured by the ratio of postvaccination geometric mean titers (cTIV vs. eTIV_f) against all three vaccine strains as assessed by egg-derived antigen and cell-derived antigen haemagglutination inhibition (HI) assay.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263" lower_limit="229" upper_limit="302"/>
                    <measurement group_id="O2" value="310" lower_limit="270" upper_limit="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" lower_limit="173" upper_limit="229"/>
                    <measurement group_id="O2" value="316" lower_limit="275" upper_limit="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (egg-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" lower_limit="163" upper_limit="210"/>
                    <measurement group_id="O2" value="159" lower_limit="141" upper_limit="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="478" lower_limit="417" upper_limit="549"/>
                    <measurement group_id="O2" value="518" lower_limit="451" upper_limit="595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306" lower_limit="267" upper_limit="350"/>
                    <measurement group_id="O2" value="444" lower_limit="388" upper_limit="508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (cell-culture-derived assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" lower_limit="160" upper_limit="203"/>
                    <measurement group_id="O2" value="135" lower_limit="120" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for A/H1N1 strain as measured by HI egg-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination GMTs had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for A/H3N2 strain as measured by HI egg-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination GMTs had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for B strain as measured by HI egg-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination GMTs had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for A/H1N1 strain as measured by HI cell-culture-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination GMTs had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for A/H3N2 strain as measured by HI cell-culture-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination GMTs had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The following hypotheses were tested for B strain as measured by HI cell-culture-derived assay:
H0i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) ≥0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) ≤0.5 (null hypothesis); H1i: log(GMTeTIV_f(i)) – log(GMTcTIV(i)) &lt;0.301 ↔ GMTcTIV(i) / GMTeTIV_f(i) &gt;0.5 (alternative hypothesis); With: GMTcTIV(i)=GMT for strain i in cTIV group; GMTeTIV_f(i)=GMT for strain i in eTIV_f group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To demonstrate non-inferiority of cTIV to eTIV_f the lower limit of the 95% confidence interval (CI) around the ratio of the postvaccination GMTs had to be &gt;0.5.</non_inferiority_desc>
            <param_type>Ratio of GMT</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Local and Systemic Reactions</title>
        <description>Safety and tolerability of cTIV and eTIV_f postvaccination.
Difference between demography and safety numbers was due to one misrandomization.</description>
        <time_frame>7 days postvaccination</time_frame>
        <population>Analysis was done on safety set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>eTIV_f</title>
            <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Local and Systemic Reactions</title>
          <description>Safety and tolerability of cTIV and eTIV_f postvaccination.
Difference between demography and safety numbers was due to one misrandomization.</description>
          <population>Analysis was done on safety set</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest tightness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficulty breathing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Facial Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;=38°C))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home due to reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic medicine used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Serious adverse events were collected throughout the study period (Day 1 - Day 180). All solicited adverse reactions were collected from Day 1 - Day 7. All unsolicited reactions were collected from Day 8 - Day 180.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>cTIV</title>
          <description>Adults 18 to &lt; 50 years of age received one dose of cell-culture-derived trivalent influenza vaccine (cTIV).</description>
        </group>
        <group group_id="E2">
          <title>eTIV_f</title>
          <description>Adults 18 to &lt; 50 years of age received one dose of egg-derived trivalent vaccine (eTIV_f).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Nasal septal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="237" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="304"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="304"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

